Mr. Andre Godin reports

NEPTUNE OBTAINS NEW US PATENT RELATING TO TREATMENT OF ALZHEIMER'S

The U.S. Patent & Trademark Office (USPTO) has granted Neptune Technologies & Bioressources Inc. a new continuation patent (U.S. patent No. 8,680,080) relating to the treatment of Alzheimer's disease.

The patent, which is the corporation's first specifically targeting neurological conditions, is granted for the U.S. market and is valid until 2022. The claims focus on treating Alzheimer's disease by administering an effective amount of a phospholipid composition, wherein the phospholipid composition comprises DHA and EPA.

"Today's announcement provides additional strength to our patent estate and highlights our commitment to continue to protect and build this valuable asset for both our nutraceutical and pharmaceutical businesses," highlighted Henri Harland, president and chief executive officer of Neptune. "Neurological disorders, such as Alzheimer's, are growing, and new methods to prevent and treat such conditions using alternative treatments are continuously being sought out. In addition to Neptune, this new patent substantially benefits our subsidiary, NeuroBioPharm, as it continues to develop omega-3 phospholipid products for neurological pharmaceutical applications."

We seek Safe Harbor.